Bacil Pharma Limited Overview
Bacil Pharma Limited is a 39-year-old Mumbai-incorporated company that is formally classified as a pharmaceutical manufacturer (pharmaceuticals, medicinal chemicals and botanical products) but has reported no revenue from operations in any year from FY2015 through FY2026. Its income is entirely "other income", mainly returns on a treasury and investment book of about ₹21 Cr created when the company raised about ₹24 Cr through a preferential allotment in FY2025. Since then, the original Shah promoter family has exited and control has passed to a new board led by Managing Director and CFO Chaitali Kalpataru Shah. Under this board the company has set up an R&D subsidiary, approved a rights issue of up to ₹50 Cr, and raised authorised capital to ₹70 Cr. In economic terms Bacil is best described as a listed shell undergoing a proposed revival into pharmaceuticals. Its equity has been highly volatile, falling about 53% over the past year.
Company's own description
In its FY2025 Management Discussion & Analysis (dated 5 September 2025), the company describes itself as primarily engaged in healthcare solutions. It says its focus is the development, manufacturing and distribution of pharmaceutical formulations: tablets, capsules, ointments, injectables and specialty products. The same MD&A acknowledges that the company earned no revenue from its core business in FY2025. It attributes the year's improvement in financial position to higher other income and cost control. Management states it is looking at operational expansion, revenue generation in core pharmaceutical verticals, further investment opportunities and product innovation. Aggregators describe the business as manufacturing and selling pharmaceuticals, medicinal chemicals and botanical products (Value Research, Tickertape). Trendlyne describes it as offering herbal extracts, heavy, medium and fine chemicals, and bulk intermediates. The MCA lists its principal activity as "Manufacture of Chemicals and Chemical Products".
Independent characterisation
The filings do not support the company's description of itself as an operating pharmaceutical business:
- Revenue from operations has been nil in every reported year from FY2015 to FY2026 (Screener.in 12-year P&L). Capital Market reports state there were no sales in Q4 FY2026 or FY2026 as a whole, and none in Q1 FY2027.
Fixed assets were about ₹1 lakh at FY2024 and nil at FY2025: (IIFL balance sheet). No manufacturing plant, inventory or trade receivables appear on the balance sheet.
Inventory and debtors have been zero: in FY2022–FY2025.
- The company's assets are almost entirely financial investments (₹21.36 Cr) and cash (₹2.86 Cr) at 31 March 2025.
Bacil Pharma is therefore, in substance, a listed corporate shell with a treasury book. Its income comes from interest, dividends and gains on investments. The investment thesis depends entirely on whether the new management can build or acquire a pharmaceutical operation using the planned rights issue proceeds.
Revenue model and mix
| Revenue type | FY2025 share | FY2026 share | Comment |
|---|---|---|---|
| Product sales | 0% | 0% | No operating revenue reported |
| Services | 0% | 0% | None reported |
| Subscription / licensing | 0% | 0% | None reported |
| Other income (treasury/investment) | 100% | 100% | ₹66.14 lakh in FY2025 (Directors' Report); about ₹122 lakh in FY2026 (derived) |
Value-chain position, customers and end-markets
Value-chain position: None in practice. The intended position is formulations manufacturing and distribution (per MD&A), but no plant, licences or distribution network is disclosed.
Customer types: Not publicly disclosed. There were no customers in FY2025–FY2026.
End-markets: Intended: the Indian domestic formulations market. Actual: none.
Data-integrity warning: Several broker profiles (ICICI Direct and others) describe "Bal Pharma Institutional division" and "Bal Pharma Units 1, 2 and 3" making tablets, APIs and IV fluids under the Bacil Pharma page. This text belongs to Bal Pharma Ltd, a different company, and is a data-vendor error. It should not be attributed to Bacil Pharma.
Strategy
Stated strategy (themes from FY2025 MD&A, paraphrased)
-
Keep a conservative and prudent approach to operations.
-
Look at future business opportunities that could generate sustainable operating revenue.
-
Explore operational expansion and revenue generation in core pharmaceutical verticals.
-
Pursue further investment opportunities and product innovation.
-
Value human capital (no headcount disclosed).
No investor day has been held and no medium-term financial targets have been published.
Initiatives announced in the last 24 months
| Date | Initiative | Detail | Status | Source |
|---|---|---|---|---|
| FY2025 | Preferential equity raise | About ₹24 Cr at ₹32 per share to non-promoters; 85 lakh shares cleared for listing on 3 Jun 2025 | Completed | Tiger Brokers; IIFL |
| 18 Jun 2026 | R&D subsidiary | Proposal for a wholly owned R&D company | Incorporated 28 Jul 2026 | ScanX |
| 26 Jun 2026 | Fund-raising framework | Up to ₹50 Cr via rights, preferential issue, convertibles or warrants | Superseded by rights decision | Whalesbook |
| 9–11 Jul 2026 | Rights issue | Up to ₹50 Cr of equity shares | Approved by board; no letter of offer, price or record date disclosed | ScanX; Groww |
| 23 Sep 2026 | Authorised capital increase | To ₹70 Cr (from ₹8 Cr in MCA records) | Approved by shareholders | ScanX |
| Sep–Oct 2026 | Debt financing | ₹5.52 Cr consolidated borrowings appear at 30 Sep 2026 | Terms not disclosed | Whalesbook |
Sustainability/ESG commitments: None disclosed.
Cost programmes: None beyond general "cost control" (MD&A FY2025).
Guidance: None.
Assessment. The strategy is a capital-raising plan without a disclosed operating plan. The proposed ₹50 Cr rights issue is about 1.7× the current market capitalisation of about ₹29 Cr. No project report, product pipeline, acquisition target or facility plan has been filed to explain the use of proceeds.
Products & Services
Assessment. No named brands, registered drug formulations, DCGI/FDA product licences, ANDAs or dossiers are disclosed in any source reviewed. The "portfolio" in company documents is a list of dosage-form categories, not a product catalogue. No flagship offering exists.
Product Portfolio
| Product line / brand | Description | Specifications | Target customer | Launch / latest version | Pricing | Status |
|---|---|---|---|---|---|---|
Tablets | Named in MD&A as a formulation category | — | — | — | — | No sales recorded FY2015–FY2026 |
Capsules | Named in MD&A | — | — | — | — | No sales recorded |
Ointments | Named in MD&A | — | — | — | — | No sales recorded |
Injectables | Named in MD&A | — | — | — | — | No sales recorded |
Specialty products | Named in MD&A | — | — | — | — | No sales recorded |
Herbal extracts / botanical products | Listed in aggregator descriptions (Trendlyne, Value Research) | — | — | Historical | — | No sales recorded |
Heavy, medium and fine chemicals; bulk intermediates | Listed in Trendlyne description, probably reflecting the pre-2015 business | — | Industrial buyers (historical) | Historical | — | No sales recorded |
“—” = not publicly disclosed.
Financial Narrative
Income statement (standalone, INR lakh)
Sources and notes: - Total income FY2022–FY2023: Tickertape (₹0.06 Cr and ₹0.11 Cr). FY2024–FY2025: FY2025 Directors' Report. FY2026 is derived (quarterly PBT sum ₹0.97 Cr plus expenses about ₹0.25 Cr).
-
Expenses: Screener.in annual expense row (₹0.16, 0.17, 0.19, 0.25, 0.25 Cr). FY2022–FY2023 PBT is derived as income minus expenses.
-
Depreciation and finance costs are approximately nil (Fyers), so EBITDA approximately equals PBT.
-
FY2024 PAT: the Directors' Report shows ₹11.38 lakh profit after tax (probably after a deferred-tax credit), while Fyers/Torus show a loss of ₹5.91–6 lakh. The movement in reserves (−₹5.43 Cr to −₹5.31 Cr) supports the ₹11 lakh figure.
-
FY2025 PAT: ₹40.05 lakh (Directors' Report) vs ₹40.42 lakh (Fyers). EPS of ₹0.30 is from Fyers.
-
FY2026 PAT: Capital Market reports net profit of ₹1.56 Cr (+290%). ScanX instead reports a "net loss of ₹61.88 lakh" vs ₹6.17 lakh the prior year. Analyst reconciliation: the ScanX numbers appear to be total comprehensive income, i.e. after other comprehensive income (OCI) fair-value losses on investments. Supporting evidence: Screener's book value of ₹17.3 per share at March 2026 implies net worth of about ₹24.8 Cr, which is below FY2025's ₹25.43 Cr despite a ₹1.56 Cr PAT. That implies an OCI loss of about ₹2.2 Cr. FY2026 EPS of about ₹1.09 is derived from Screener's P/E of 45.4 at ₹49.4.
-
Q4 FY2026: PAT ₹0.62 Cr (Capital Market) vs a ₹164.14 lakh loss (ScanX), consistent with the same PAT/TCI distinction.
Commentary. The P&L has no operating engine. From FY2022 to FY2024, interest on a cash balance of about ₹1 Cr did not cover listing and administrative costs of ₹16–19 lakh. The FY2025 inflection is purely balance-sheet driven: the roughly ₹24 Cr preferential raise was invested, and other income rose about five times to ₹66 lakh. FY2026 PAT rose again to about ₹1.56 Cr, but Q1 FY2026 alone contributed ₹0.67 Cr. That points to lumpy realised gains rather than recurring yield. Mark-to-market losses booked through OCI turned comprehensive income negative. In FY2027 to date, income has collapsed: H1 FY2027 total income was ₹0.18 Cr vs ₹1.06 Cr in H1 FY2026 (Whalesbook), and the company is back to losses.
Margins. Gross, operating, EBITDA and net margins on operating revenue are not meaningful because the denominator is zero. Aggregator "net margin" figures (for example, 563.64% for Q4 FY2026 on IndMoney) are computed on other income and should be disregarded.
Revenue CAGR (FY2022–FY2026): Not meaningful for operating revenue. Total-income CAGR is about 113% (derived), but this reflects a capital injection, not organic growth.
Balance sheet (standalone, INR lakh)
Sources: IIFL/IndiaInfoline standalone balance sheet FY2022–FY2025. FY2026 total assets ₹2,739.26 lakh (ScanX, from the FY2026 audited results; FY2025 shown there as ₹2,560.02 lakh). FY2026 cash ₹0.57 Cr and nil borrowings (Whalesbook, Q2 FY2027 results comparison). FY2026 equity derived from Screener book value ₹17.3 × about 1.435 crore shares.
Conflict: MarketsMojo shows Mar 2024 share capital of ₹23.71 Cr and shareholders' funds of ₹24.65 Cr. This is inconsistent with IIFL (₹6.53 Cr / ₹1.22 Cr) and with the reserve trajectory. IIFL is treated as correct.
Post-period development. As of 30 September 2026, consolidated borrowings were ₹5.52 Cr (vs nil at 31 March 2026) and consolidated cash was ₹0.97 Cr (Whalesbook). The lender, terms and use of the borrowing are not publicly disclosed. This is the company's first material debt in the available record.
Cash flow (INR lakh)
Cash-flow statements are not available in the sources reviewed. FY2025 equity raised is derived: increase in share capital of ₹7.44 Cr plus about ₹16.4 Cr of share premium (7.44 million shares × ₹22) ≈ ₹23.8 Cr. Capex is inferred as nil from the absence of fixed-asset additions.
Ratios
ROE/ROA are derived on average equity/assets. The FY2026 ROE of 6.2% matches Screener's reported 6.21%, and FY2026 ROCE of 3.93% is from Screener. MarketInOut reports ROE 5.26%, ROA 5.06% and ROIC −0.97% on a trailing basis. Interest coverage is not meaningful (negligible finance cost). The cash conversion cycle is not applicable (no inventory, receivables or payables).
Interpretation. Returns are thin. A 6% ROE in FY2026, earned on a treasury book, is below the yield of an Indian government bond. Because operating ROIC is negative, every rupee of administrative cost depends on investment income. The balance sheet was conservative (debt-free at FY2026), but the new ₹5.52 Cr consolidated borrowing changes that profile.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Pharmaceuticals: revenue from operations (INR Lakh) | 0 | 0 | 0 |
Other income, non-segment (INR Lakh) | 13 | 66 | 122 |
Segment pre-tax result (INR Lakh) | -6 | 41 | 97 |
Contribution of pharma segment to total revenue (%) | 0 | 0 | 0 |
Group Entities
| Entity | Relationship | Incorporated | Activity | Source |
|---|---|---|---|---|
Bacil Pharma Limited | Listed parent | 1987 | Holding/treasury; intended pharma formulations | BSE |
Bacil Research & Development Pvt Ltd | Wholly owned subsidiary | 28 Jul 2026 | Pharmaceutical R&D (stated intent) | ScanX |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Lakh) | 0 | 0 | 0 | 0 | 0 |
Total income incl. other income (INR Lakh) | 6 | 11 | 13 | 66 | 122 |
Total expenses (INR Lakh) | 16 | 17 | 19 | 25 | 25 |
Gross profit (INR Lakh) | 0 | 0 | 0 | 0 | 0 |
Operating income ex-other income (INR Lakh) | -16 | -17 | -19 | -25 | -25 |
EBITDA incl. other income (INR Lakh) | -10 | -6 | -6 | 41 | 97 |
Pre-tax income (INR Lakh) | -10 | -6 | -6 | 41 | 97 |
Net income, PAT (INR Lakh) | — | — | 11 | 40 | 156 |
Total comprehensive income (INR Lakh) | — | — | — | -6 | -62 |
EPS basic (INR) | — | — | — | 0.30 | 1.09 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Lakh) | 126 | 113 | 137 | 2,560 | 2,739 |
Cash and equivalents (INR Lakh) | 23 | 3 | 4 | 286 | 57 |
Investments (INR Lakh) | 31 | 43 | 61 | 2,136 | — |
Total debt (INR Lakh) | 3 | 2 | 10 | 16 | 0 |
Net debt (INR Lakh) | -20 | -1 | 6 | -270 | -57 |
Equity share capital (INR Lakh) | 653 | 653 | 653 | 1,397 | — |
Reserves (INR Lakh) | -530 | -543 | -531 | 1,146 | — |
Shareholders' equity (INR Lakh) | 123 | 110 | 122 | 2,543 | 2,483 |
Goodwill and intangibles (INR Lakh) | 0 | 0 | 0 | 0 | — |
Net working capital (INR Lakh) | 60 | 54 | 59 | 132 | — |
Fixed assets (INR Lakh) | 1 | 1 | 1 | 0 | — |
Balance Sheet — Capital expenditure
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Capital expenditure (INR Lakh) | 0 | 0 | 0 | 0 | — |
Equity raised (INR Lakh) | 0 | 0 | 0 | 2,380 | — |
Dividends paid (INR Lakh) | 0 | 0 | 0 | 0 | 0 |
Buybacks (INR Lakh) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | — | — | 9.5 | 3.0 | 6.2 |
ROA (%) | — | — | 8.7 | 3.0 | 5.9 |
ROCE (%) | — | — | — | — | 3.9 |
Debt to equity (x) | 0.02 | 0.02 | 0.08 | 0.01 | 0.00 |
Net debt to EBITDA (x) | — | — | — | -6.6 | -0.6 |
Asset turnover on operating revenue (x) | 0 | 0 | 0 | 0 | 0 |
Results by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India: revenue from operations (INR Lakh) | 0 | 0 | 0 |
Outside India: revenue from operations (INR Lakh) | 0 | 0 | 0 |
India: total income incl. other income (INR Lakh) | 13 | 66 | 122 |
Share Price History
| Date | Price (INR) | Market cap (INR Cr) | Source |
|---|---|---|---|
4 Aug 2025 | 37.58 | — | Trendlyne |
26 Dec 2025 | 34.23 | — | ICICI Direct |
2 Jan 2026 | 38.35 | 55 | Business Standard |
2 Apr 2026 | 52.60 | — | ICICI Direct |
27 May 2026 | 51.09 | 73 | Value Research |
3 Jun 2026 | 48.01 | 72.22 | Torus Digital |
9 Jul 2026 | 38.36 | 55.06 | IIFL |
7 Aug 2026 | 16.93 | 24.30 | IIFL |
14 Aug 2026 | 13.12 | — | ICICI Direct |
~19–20 Oct 2026 | 20.34 | ~29 (derived) | ScanX |
Share Price & Returns
| Horizon | Return | As of | Source |
|---|---|---|---|
1 month | −3.60% | Oct 2026 | ScanX |
6 months | −62.59% | Oct 2026 | ScanX |
1 year | −52.97% | Oct 2026 | ScanX |
3 years (CAGR) | +25.20% | 7 Aug 2026 | IIFL |
5 years (CAGR) | +21.79% | 7 Aug 2026 | IIFL |
Valuation Multiples
| Multiple | Bacil Pharma | Peer reference | Comment |
|---|---|---|---|
P/E (FY2026 EPS about ₹1.09) | ~18.7× | Peer median about 47× (Value Research, May 2026) | EPS is non-operating and non-recurring |
P/B (book about ₹17.3) | ~1.2× | Peer median about 3.9× (Value Research, May 2026) | Book is mostly investments, marked to market |
Capital Markets
| Item | Detail |
|---|---|
Analyst consensus | None (0 analysts, Simply Wall St) |
Dividend history / policy | No dividend paid in the record; no stated policy |
Credit ratings (Moody's / S&P / Fitch / domestic) | Not rated |
Debt maturity profile | Not disclosed (₹5.52 Cr consolidated borrowings at 30 Sep 2026) |
Beta | −0.085 (Snowball) to 0.47 (Simply Wall St); not reliable given illiquidity |
Liquidity | BSE-only; daily volumes about 20,000–1,44,000 shares in sampled sessions (Fyers; Trendlyne) |
Circuit band | Frequent 5% moves (for example −5.00% on several sampled days), consistent with a narrow price band |
Analyst Conclusions
Management guidance and consensus
Guidance: None issued. Management's stated intent (FY2025 MD&A) is to explore operational expansion and revenue in core pharmaceutical verticals.
Consensus: No analyst coverage, so no consensus growth expectations exist.
Bull case
-
Capital plus listing equals an option value. With about ₹21 Cr of investments (FY2025) and a ₹50 Cr rights issue authorised, Bacil could fund a small formulations or loan-licence business, or merge in an operating company. The stock trades at about 1.2× a book made up mostly of liquid assets.
-
The board has a clear shareholder mandate. Approval of 99.93–100% for all resolutions, and the creation of an R&D subsidiary, suggest a coordinated plan is being executed.
-
The de-rating may have overshot. A fall of about 63% in six months took the price to roughly book value. Any credible announcement of an operating plan or acquisition could re-rate the stock from a low base, as the 3-year CAGR of 25% shows it has done before.
Bear case
-
No business, collapsing income. Nil sales for 12 years and H1 FY2027 income down 83% leave a shell burning cash. The ₹5.52 Cr of new borrowings adds leverage with no visible earning asset.
-
Dilution and governance risk. A rights issue of up to 1.7× the market cap, the absence of a classified promoter, a vacant compliance officer post, a revised quarterly result and GSM surveillance create a high-risk governance profile.
-
Earnings quality is poor. FY2026 PAT (+₹1.56 Cr) and total comprehensive income (−₹0.62 Cr) diverge, which suggests reported profits overstate economic value creation. Book value fell year on year.
Catalysts and monitorables (next 12 months)
| Monitorable | What to watch |
|---|---|
| Rights issue | Filing of the letter of offer; price, ratio, record date; use of proceeds; subscription levels |
| Use of borrowings | Disclosure of lender, terms and purpose of the ₹5.52 Cr |
| Operating plan | Any plant acquisition, loan-licence agreement, product registrations or acquisition target |
| R&D subsidiary | Capitalisation, staffing, research agenda |
| Compliance | Appointment of a new CS within the statutory window; quarterly filings on time |
| Control | SAST filings; any promoter reclassification or open offer |
| Surveillance | GSM stage changes and any further BSE queries |
| Results | Q3 FY2027 (due around February 2027) and FY2027 audited results (May 2027): income, OCI, borrowing levels |
Analyst verdict
Bacil Pharma Limited is not, on the evidence of its own filings, a pharmaceutical company in any operating sense. It is a 1987-vintage BSE shell. It has reported no revenue from operations for twelve consecutive fiscal years, owns no fixed assets, and holds about ₹21–27 Cr of financial assets that came almost entirely from a FY2025 preferential allotment at ₹32 per share. Since then the founding Shah promoter family has sold out and a new board under MD and CFO Chaitali K. Shah has taken over. That board has created an R&D subsidiary, approved a rights issue of up to ₹50 Cr and raised authorised capital to ₹70 Cr. However, it has not disclosed a product pipeline, facility, licence, partner or acquisition that would turn this capital into an operating business.
The financial record argues for caution. FY2026 reported profit of about ₹1.56 Cr depended on treasury gains, and total comprehensive income was negative because of investment write-downs. H1 FY2027 income fell by more than 80%, the company returned to losses, and it took on ₹5.52 Cr of borrowings with undisclosed terms. Governance signals point the same way: the compliance officer post has been vacant since October 2026, a director-appointment intimation was withdrawn, a quarterly result was revised, auditors were changed, and the stock is under exchange surveillance. The share price has fallen about 53% in a year and about 63% in six months, and it now trades near book value.
The only real source of value is optionality: a listed, debt-light platform that a credible sponsor could use to build or inject a business. Until management files a rights offer document with a specific, verifiable use of proceeds, the shares are best treated as a speculative, governance-sensitive special situation rather than a pharmaceutical investment. Fundamental valuation is not meaningful, and the main risk to an investor is losing capital through dilution and leakage of the investment book.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | DIN | Tenure / appointment | Prior roles | Source |
|---|---|---|---|---|---|
Chaitali Kalpataru Shah | Managing Director and CFO (redesignated from Executive Director at the 39th AGM, 23 Sep 2026) | 11,167,778 | Director since c.2025 (exact date not disclosed); MD from Sep 2026 | — | ScanX AGM report |
Omprakash Pyarelal Sonar | Independent Director (reappointed at 39th AGM) | 11,031,877 | c.2025 onward | — | ScanX |
Vivek Mukesh Yadav | Independent Director (reappointed at 39th AGM) | 11,033,957 | c.2025 onward | — | ScanX |
Mahesh Singh | Independent Director (appointed 25 Aug 2026; regularised at AGM) | 11,814,569 | Since Aug 2026 | — | ScanX; Groww |
Anil (Shiv Charan) Singh | Non-Executive Non-Independent Director (appointed 25 Aug 2026; regularised at AGM) | 09,338,444 | Since Aug 2026 | An "Anil Singh" is listed as a director of Baxil Pharma Pvt Ltd (Delhi). Whether this is the same person is unconfirmed | ScanX; InsiderBiz |
Company Secretary & Compliance Officer | Vacant since 8 Oct 2026 (Dikshant Singh Panwar resigned, citing personal and professional commitments) | — | — | — | ScanX |
“—” = not publicly disclosed.
Board of Directors — Prakash Bhoorchand Shah
| Name | Former role | Exit | Source |
|---|---|---|---|
Prakash Bhoorchand Shah | Promoter / Director | Sold shares 2024–25; promoter group exited by Mar 2026 | Companydetails.in; Simply Wall St |
Suman Prakash Shah | Promoter / Director | Disposed of entire stake (FY2026) | ScanX; Companydetails.in |
Mehul Hasmukhbhai Shah | Executive Director | Resigned 24 Feb 2025 | Directors' Report FY2025 |
Ganpat Dhondu Salekar | Manager | — | Vogue Commercial |
Bhavana Tak | Company Secretary & Compliance Officer | — | Vogue Commercial |
Shirish Suryakant Shetye; Lalit Jain; Jayesh Ramchandra Patil | Directors (historical) | — | Companydetails.in |
Avani Savjibhai Godhaniya | Proposed Independent Director (effective 9 Jul 2026) | Status unclear after withdrawal and re-proposal of appointments | ScanX |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Date of data | Source |
|---|---|---|---|
Promoter & promoter group | 0% (Torus: fell from 0.08% in Dec 2025 to 0% in Mar 2026). Conflict: Angel One shows 10.6% promoter holding, possibly reflecting reclassification of new controllers or stale data | Mar 2026 | Torus Digital; Angel One |
Nikita Hiren Patel | 10.07% (14,44,844 shares) after selling 7.10% | 24 Jun 2026 | Whalesbook |
Niraj Rajnikant Shah | 6.44% (9,25,000 shares) | 24 Jun 2026 | Whalesbook |
GB Logistics Commerce Limited | 6.18% (8,87,300 shares) | Date not stated (2025) | Simply Wall St |
Parikshit Notaria | 1.16% | 2025 | Simply Wall St |
Saroj Mehta | 1.16% | 2025 | Simply Wall St |
Randeep Singh | 0.84% | 2025 | Simply Wall St |
Manubhai Shah | 0.72% | 2025 | Simply Wall St |
Gaurang Shah | 0.66% | 2025 | Simply Wall St |
Jayesh Patel | 0.54% | 2025 | Simply Wall St |
Navin Mehta | 0.43% | 2025 | Simply Wall St |
FIIs / DIIs / mutual funds | 0% / 0% / 0% | 2026 | Angel One |
Retail / public | About 89.4% | 2026 | Angel One |
Competitive Landscape
Key Competitors
| Company | Exchange | Relevance | Source for peer listing |
|---|---|---|---|
Godavari Drugs | BSE | Micro-cap pharma peer | Business Standard |
Lasa Supergenerics | BSE/NSE | Micro-cap API peer | Business Standard |
Vasundhara Rasayans | BSE | Micro-cap chemicals peer | Business Standard |
Welcure Drugs & Pharmaceuticals | BSE | Micro-cap shell-like pharma peer | Business Standard |
Biofil Chemicals & Pharmaceuticals | BSE | Micro-cap pharma peer | Business Standard |
Vista Pharmaceuticals | BSE | Micro-cap pharma peer | Business Standard |
Fredun Pharmaceuticals | BSE | Small formulations peer | Nirmal Bang |
Sun Pharmaceutical Industries | NSE/BSE | Aspirational formulations leader | Tickertape peer list |
Cipla | NSE/BSE | Formulations leader | Tickertape |
Dr. Reddy's Laboratories | NSE/BSE | Formulations leader | Tickertape |
Mankind Pharma | NSE/BSE | Domestic formulations leader | Tickertape |
Zydus Lifesciences | NSE/BSE | Formulations leader | Tickertape |
Peer Comparison FY2026
| Metric | Bacil Pharma FY2026 | Typical BSE micro-cap pharma shell |
|---|---|---|
Operating revenue (INR Cr) | 0 | Often nil to low single digits |
Operating margin | Not meaningful (negative opex) | — |
R&D intensity | Not disclosed (negligible) | — |



